Perspective
Our work in Perspective
-
Does Medicare Advantage Deliver Better Care for Persons Living With Dementia Than Traditional Medicare?
With data available from CMS on all Medicare beneficiaries enrolled in private plans and traditional Medicare, researchers at the USC Schaeffer Center are driving new research on how payment structures impact the care of persons living with dementia.
Categorized in -
The Inflation Reduction Act’s Harms Go Beyond Drug Pricing — They’re Threatening Your Medicare
The IRA threatens to deliver disaster across the entire innovation, financing and distribution system for prescription drugs.
Categorized in -
Can a Free Virtual Outreach Series Increase Alzheimer’s Disease Awareness?
Lack of awareness remains one of the biggest barriers to participation in Alzheimer’s disease clinical trials, especially among underrepresented groups. New ways to connect with communities and to expand access to clinical trials include a virtual Alzheimer’s disease informational series, which reveals important insights about how people engage with virtual content differently than at in-person events.
Categorized in -
Biden’s Hepatitis C Initiative Needs Help from the Private Market
Instead of this massive nationalized program, the White House could make four administrative changes that would jump-start private-sector solutions in each state.
Categorized in -
Want Lower Obesity Drug Costs? Medicare Holds the Key
Medicare coverage will catalyze market competition
Categorized in -
Comments in Response to a CBO Call for New Research on Obesity
While there are significant data and methodological challenges to be overcome, there are better alternatives to simplistically extrapolating from the real-world data on AOM use that is currently available.
Categorized in -
How the Secrecy of Middlemen Inflates Drug Prices
Drug costs can be driven down if market forces are allowed to target those profits, but first everyone needs to know what is being charged, and by whom to whom.
Categorized in -
Congress Wants a Better Value. So Why Are They Eliminating Performance Based Payment?
Doctors, pharmacists, and even drug company sales reps are all paid based on performance because it incentivizes desired outcomes.
Categorized in -
Government And Commercial Insurer Payment Rates to Hospitals: A Commentary on Priselac
Paul Ginsburg discusses how for decades, stakeholders have argued about whether competition or regulation should be the approach to constrain health care spending. By having chosen neither, he argues, our nation now finds itself with a much larger challenge. The magnitude of our health care affordability problem cries out for pursuing both competition and regulation.
Categorized in -
We Can Find Cancers with a Simple Blood Test
As a cancer researcher and a health economist, we’ve seen up close through our lab and consulting work the revolution contained in a blood draw. But cancer detection blood tests aren’t built into annual physicals like standard blood tests, and so far they aren’t covered by insurance.
Categorized in